Novo Nordisk, a leading pharmaceutical company specializing in diabetes care and obesity treatments, has announced plans to reduce approximately 4% of its workforce globally. This restructuring is part of a broader strategy to streamline operations and address decreased sales figures within the weight-loss drug market. The company anticipates a significant reduction in positions across various departments, including research and development, manufacturing, and administrative roles. The move is being undertaken to improve operational efficiency and focus on key therapeutic areas. The impact on employees is expected to be felt across multiple locations.
Credits: Al Jazeera – Breaking News, World News and Video from Al Jazeera